Alvotech Feed

	Est. tid*
2024-11-13	-	Kvartalsrapport 2024-Q3
2024-08-16	-	Kvartalsrapport 2024-Q2
2024-05-17	-	Kvartalsrapport 2024-Q1
2023-11-14	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-06-06	-	Årsstämma
2023-05-19	-	Kvartalsrapport 2023-Q1

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

2025-06-06 14:30:00 Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

2025-06-06 14:30:00 Alvotech tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans í Miami

2025-06-06 14:30:00 Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

2025-06-05 08:55:00 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

2025-06-05 08:55:00 Alvotech og Dr. Reddys ganga til samstarfs um þróun hliðstæðu við krabbameinslyfið Keytruda

2025-06-05 08:55:00 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

2025-06-05 04:29:32 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

2025-06-05 01:55:00 Alvotech lýkur lokuðu útboði á alls 7.500.000 sænskum heimildarskírteinum (SDR) og hlutabréfum á genginu 100 sænskar krónur fyrir hvert SDR og 1.320,83 íslenskar krónur fyrir hvern hlut, að heildarfjárhæð 750 milljónir sænskra króna

2025-06-05 01:55:00 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

2025-06-04 17:32:42 Alvotech ráðgerir útboð til stofnanafjárfesta á um 7,5 milljónum sænskra heimildarskírteina og hlutabréfum

2025-06-04 17:32:42 Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

2025-06-04 13:45:00 Alvotech lýkur við kaup á rannsóknaraðstöðu Xbrane og fyrirhugaðri hliðstæðu við Cimzia 1440,00 ISK | 0,00%

2025-06-04 13:45:00 Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® 1440,00 ISK | 0,00%

2025-06-02 15:15:00 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY 1445,00 ISK | -0,34%

2025-06-02 15:15:00 Alvotech fundar með fjárfestum á árlegri heilbrigðisráðstefnu Jefferies fjárfestingabankans í New York og flytur kynningu 1445,00 ISK | -0,34%

2025-06-02 15:15:00 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY 1445,00 ISK | -0,34%

2025-05-28 12:15:00 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe 1445,00 ISK | +3,58%

2025-05-28 12:15:00 Advanz Pharma semur við Alvotech um rétt til markaðssetningar þriggja fyrirhugaðra hliðstæða til viðbótar í Evrópu 1445,00 ISK | +3,58%

2025-05-28 12:15:00 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe 1445,00 ISK | +3,58%

2025-05-26 20:06:57 Aðalfundur Alvotech boðaður 25. júní 2025

2025-05-26 20:06:57 Alvotech Annual General Meeting to be held June 25, 2025

2025-05-23 18:11:25 Viðskipti stjórnenda og tengdra aðila 1275,00 ISK | -1,16%

2025-05-23 18:11:25 Transactions of Managers and Closely Associated Persons 1275,00 ISK | -1,16%

2025-05-19 09:15:00 Alvotech semur við fjárfestingabankann DNB Carnegie um viðskiptavakt á Nasdaq markaðnum í Stokkhólmi 1330,00 ISK | -1,48%

2025-05-19 09:15:00 Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm 1330,00 ISK | -1,48%

2025-05-19 08:30:00 Viðskipti með bréf í Alvotech hefjast á Nasdaq markaðnum í Stokkhólmi í dag 1330,00 ISK | -1,48%

2025-05-19 08:30:00 Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today 1330,00 ISK | -1,48%

2025-05-16 19:52:25 Alvotech tilkynnir niðurstöðu útboðs í tengslum við skráningu félagsins á Nasdaq markaðinn í Stokkhólmi 1350,00 ISK | +2,66%

2025-05-16 19:52:25 Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm 1350,00 ISK | +2,66%

2025-05-16 16:28:31 Viðskipti stjórnenda og tengdra aðila 1350,00 ISK | +2,66%

2025-05-16 16:28:31 Transactions of Managers and Closely Associated Persons 1350,00 ISK | +2,66%

2025-05-13 11:16:31 Leiðrétting: Viðskipti stjórnenda og tengdra aðila 1345,00 ISK | -2,54%

2025-05-13 10:05:00 Viðskipti stjórnenda og tengdra aðila 1345,00 ISK | -2,54%

2025-05-13 10:05:00 Transactions of Managers and Closely Associated Persons 1345,00 ISK | -2,54%

2025-05-09 14:00:00 Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada 1305,00 ISK | +9,66%

2025-05-09 14:00:00 Alvotech fundar með fjárfestum á heilbrigðisráðstefnu BofA Securities í Las Vegas og situr fyrir svörum 1305,00 ISK | +9,66%

2025-05-09 14:00:00 Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada 1305,00 ISK | +9,66%

2025-05-09 13:17:28 Viðskipti stjórnenda og tengdra aðila 1305,00 ISK | +9,66%

2025-05-09 13:17:28 Transactions of Managers and Closely Associated Persons 1305,00 ISK | +9,66%

2025-05-08 08:30:00 Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm 1190,00 ISK | +14,42%

2025-05-07 22:45:00 Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2025 og kynnir nýjustu áfanga í rekstri félagsins 1040,00 ISK | -0,48%

2025-05-07 22:45:00 Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update 1040,00 ISK | -0,48%

2025-05-07 11:00:00 Mögulegir tollar á innflutning lyfja til Bandaríkjanna hefðu hverfandi áhrif á tekjur Alvotech á árinu 1040,00 ISK | -0,48%

2025-05-07 11:00:00 Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 1040,00 ISK | -0,48%

2025-05-05 13:00:00 Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) 1070,00 ISK | +3,38%

2025-05-05 13:00:00 Selarsdi hliðstæðan fær fullan útskiptileika við frumlyfið Stelara í Bandaríkjunum 1070,00 ISK | +3,38%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Alvotech

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden